{"uid":"cap_xKL6eXG9Hcjvsg7co2wq3","slug":"hfa-icos-baseline-cv-risk-calculator-for-multiple-myeloma-therapy-f989da4c","name":"HFA-ICOS Baseline CV Risk Calculator for Multiple Myeloma Therapy","description":"Lyon 2020 HFA-ICOS baseline CV risk before proteasome inhibitors and immunomodulatory drugs for multiple myeloma. Returns risk_level low, medium, high, or very_high plus medium_points and the paper's expert-opinion cardiotoxicity_guide. Age >=75 is High; 65-74 is Medium 1. Caller assigns labs, BMI >30, and high-dose dexamethasone. magent does not examine the patient or read imaging. Not a medical device or treatment order.","url":"https://api.magentlab.com/api/calc/hfa_icos_myeloma","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"headers":{"type":"object","additionalProperties":{"type":"string"}},"queryParams":{"type":"object","required":["age_years","lvef_percent","heart_failure_or_cardiomyopathy","prior_proteasome_inhibitor_cardiotoxicity","venous_thrombosis","cardiac_amyloidosis","arterial_vascular_disease","prior_immunomodulatory_drug_cv_toxicity","elevated_bnp","prior_anthracycline","arrhythmia","elevated_troponin","left_ventricular_hypertrophy","hypertension","diabetes","hyperlipidemia","ckd","family_history_thrombophilia","prior_thoracic_spine_radiotherapy","high_dose_dexamethasone","current_or_significant_smoker","obesity"],"properties":{"ckd":{"type":"boolean","description":"Chronic kidney disease as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not compute eGFR."},"obesity":{"type":"boolean","description":"Obesity (BMI >30 kg/m2) as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not compute BMI."},"diabetes":{"type":"boolean","description":"Diabetes mellitus as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not assay HbA1c."},"age_years":{"type":"integer","description":"Age in years (18-100, integer). Lyon 2020 myeloma-therapy table: >=75 High; 65-74 Medium 1; <65 no age factor. Highest matching band only."},"arrhythmia":{"type":"boolean","description":"Arrhythmia (Lyon 2020 Medium 2). true or false as assigned by the caller. magent does not read a rhythm strip."},"elevated_bnp":{"type":"boolean","description":"Baseline BNP or NT-proBNP above the local laboratory ULN as assigned by the caller (Lyon 2020 High). true or false. magent does not assay natriuretic peptides."},"hypertension":{"type":"boolean","description":"Hypertension as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not measure blood pressure."},"lvef_percent":{"type":"integer","description":"LVEF percent (10-80, integer). Lyon 2020: <50 High; 50-54 Medium 2; >=55 no LVEF factor. Highest matching printed band only. magent does not read imaging."},"hyperlipidemia":{"type":"boolean","description":"Hyperlipidemia as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not assay lipids."},"elevated_troponin":{"type":"boolean","description":"Baseline troponin above the local laboratory ULN as assigned by the caller (Lyon 2020 Medium 2). true or false. magent does not assay troponin."},"venous_thrombosis":{"type":"boolean","description":"Venous thrombosis (DVT or PE) (Lyon 2020 Very high). true or false as assigned by the caller. magent does not diagnose thrombosis."},"cardiac_amyloidosis":{"type":"boolean","description":"Cardiac amyloidosis (Lyon 2020 Very high). true or false as assigned by the caller. magent does not read imaging or biopsy."},"prior_anthracycline":{"type":"boolean","description":"Prior anthracycline exposure (Lyon 2020 High). true or false as assigned by the caller."},"high_dose_dexamethasone":{"type":"boolean","description":"High-dose dexamethasone (>160 mg/month) as assigned by the caller (Lyon 2020 Medium 1). true or false. magent does not compute a steroid dose."},"arterial_vascular_disease":{"type":"boolean","description":"Arterial vascular disease (IHD, PCI, CABG, stable angina, TIA, stroke, or PVD) as one caller bool (Lyon 2020 Very high). true or false. magent does not diagnose vascular disease."},"family_history_thrombophilia":{"type":"boolean","description":"Family history of thrombophilia (Lyon 2020 Medium 1). true or false as assigned by the caller. magent does not take a family history."},"left_ventricular_hypertrophy":{"type":"boolean","description":"Left-ventricular hypertrophy (Lyon 2020 Medium 1). true or false as assigned by the caller. magent does not read imaging."},"current_or_significant_smoker":{"type":"boolean","description":"Current smoker or significant smoking history (Lyon 2020 Medium 1). true or false as assigned by the caller."},"heart_failure_or_cardiomyopathy":{"type":"boolean","description":"Heart failure or cardiomyopathy (Lyon 2020 Very high). true or false as assigned by the caller. magent does not examine the patient or read imaging."},"prior_thoracic_spine_radiotherapy":{"type":"boolean","description":"Prior thoracic-spine radiotherapy (Lyon 2020 Medium 1). true or false as assigned by the caller."},"prior_immunomodulatory_drug_cv_toxicity":{"type":"boolean","description":"Prior immunomodulatory-drug cardiovascular toxicity (Lyon 2020 High). true or false as assigned by the caller."},"prior_proteasome_inhibitor_cardiotoxicity":{"type":"boolean","description":"Prior proteasome-inhibitor cardiotoxicity (Lyon 2020 Very high). true or false as assigned by the caller."}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}},"responseSchema":null,"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.005","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.005/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_gB_6J1gkGQc93fscL7m7B","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.005","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Calculates the Lyon 2020 HFA-ICOS baseline cardiovascular risk level (low/medium/high/very_high) before initiating proteasome inhibitors or immunomodulatory drugs for multiple myeloma.","exampleAgentPrompt":"What is the Lyon 2020 HFA-ICOS baseline cardiovascular risk level for a 70-year-old multiple myeloma patient with an LVEF of 52%, hypertension, diabetes, CKD, elevated BNP, prior anthracycline exposure, and BMI over 30 who is about to start a proteasome inhibitor — no prior cardiotoxicity from PI or IMiD, no cardiac amyloidosis, no arrhythmia, no elevated troponin, no LVH, no hyperlipidemia, no thrombosis, no family history of thrombophilia, no prior thoracic radiotherapy, not on high-dose dexamethasone, and not a smoker?","exampleUseCases":[{"title":"Pre-bortezomib CV risk screening","prompt":"Before we start bortezomib for our 78-year-old myeloma patient, can you calculate their HFA-ICOS cardiovascular risk? They have an LVEF of 48%, heart failure, no prior PI cardiotoxicity, no IMiD CV toxicity, no venous thrombosis, no cardiac amyloidosis, no arterial vascular disease, elevated troponin, elevated BNP, prior anthracycline, left ventricular hypertrophy, hypertension, diabetes, hyperlipidemia, CKD, no family thrombophilia history, no prior thoracic radiotherapy, not on high-dose dex, non-smoker, and not obese."},{"title":"Lenalidomide pre-therapy risk in young fit patient","prompt":"Run the Lyon 2020 HFA-ICOS myeloma cardiotoxicity risk score for a 58-year-old patient starting lenalidomide — LVEF 60%, no heart failure, no prior PI or IMiD cardiotoxicity, no venous thrombosis, no cardiac amyloidosis, no arterial vascular disease, normal BNP, no prior anthracycline, no arrhythmia, normal troponin, no LVH, no hypertension, no diabetes, mildly elevated lipids, no CKD, no family thrombophilia history, no thoracic radiotherapy, on high-dose dexamethasone, non-smoker, BMI 28."},{"title":"Cardiomyopathy patient risk before IMiD","prompt":"What's the HFA-ICOS baseline CV risk for a 66-year-old myeloma patient with cardiomyopathy, LVEF of 38%, no prior proteasome inhibitor cardiotoxicity, prior IMiD CV toxicity, known arterial vascular disease, elevated BNP, prior anthracycline, arrhythmia, elevated troponin, LVH, hypertension, type 2 diabetes, hyperlipidemia, CKD, family history of thrombophilia, no thoracic radiotherapy, high-dose dex, current smoker, and obesity?"}],"resultDescription":"Returns a JSON object with: risk_level (one of low, medium, high, or very_high) per the Lyon 2020 HFA-ICOS myeloma-therapy table; medium_points (the tally of medium-tier risk factors contributing to score elevation); and cardiotoxicity_guide containing the paper's expert-opinion narrative recommendations for monitoring and management based on the assigned risk tier. The caller is responsible for correctly assigning all boolean lab and clinical flags; the service performs only the scoring computation.","failureModes":["Missing required query parameters returns a 400 error — all 22 boolean flags plus age_years and lvef_percent must be supplied","age_years outside the 18–100 integer range may return a validation error","lvef_percent outside 0–100 may return a validation error","Incorrect caller assignment of lab values (e.g., BNP, troponin) leads to inaccurate scoring — the service trusts caller-supplied booleans","Payment failure or missing x402 header returns 402 Payment Required"],"whenToPreferThis":"Use this endpoint when you need the standardized Lyon 2020 HFA-ICOS cardiovascular risk tier (low/medium/high/very_high) specifically for multiple myeloma patients before starting proteasome inhibitors (e.g., bortezomib, carfilzomib) or immunomodulatory drugs (e.g., lenalidomide, thalidomide). Choose this over generic CV risk calculators (e.g., Framingham, SCORE2) when the clinical context is myeloma cardio-oncology and the scoring framework must match published HFA-ICOS myeloma guidance. Not suitable for general cardiac risk outside the myeloma-therapy indication, for patients already on treatment, or for treatment ordering.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T07:20:24.722Z","isFirstParty":false}